AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.6 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Research progress on glutamine metabolism and tumor drug resistance mechanisms

Yiwen Chen1, Jingjing Zhang2, Xiongfei Zhang3 ( )
School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023
Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029
Department of Biochemistry and Molecular Biology, Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China
Show Author Information

Abstract

Malignant tumor cells undergo profound metabolic reprogramming, manifested by a markedly enhanced capacity for the uptake of specific metabolic substrates, most notably glutamine (Gln). This metabolic adaptation not only provides essential precursors to support aberrantly active glycolysis and mitochondrial oxidative phosphorylation but also disrupts the homeostatic balance of carbohydrate, lipid, and amino acid metabolism, thereby directly contributing to the adaptive resistance of tumor tissues to chemotherapeutic agents. Despite its significance, a systematic understanding of how tumor cells modulate Gln metabolic plasticity to evade drug-induced cytotoxicity remains elusive. Furthermore, there is a notable lack of in-depth analyses addressing the context-dependent variability of Gln metabolism across different cancer types and microenvironments, as well as the underlying causes of the failures in clinical translation. This review systematically delineates the key regulatory roles and mechanistic pathways through which Gln metabolism drives the acquisition of drug resistance in malignant tumors. For the first time, we propose a three-dimensional resistance framework-termed the “Gln metabolism-microenvironment-immune evasion” model and identify three major bottlenecks inherent in current targeted therapeutic strategies. Collectively, this review aims to establish a theoretical foundation and provide methodological insights to inform and improve clinical treatment strategies for drug-resistant malignant tumors.

CLC number: R730.5 Document code: A Article ID: 1007-4368(2026)10-1567-17

References

【1】
【1】
 
 
Journal of Nanjing Medical University (Natural Sciences)
Pages 1567-1583

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Chen Y, Zhang J, Zhang X. Research progress on glutamine metabolism and tumor drug resistance mechanisms. Journal of Nanjing Medical University (Natural Sciences), 2026, 46(10): 1567-1583. https://doi.org/10.7655/NYDXBNSN260141

5

Views

0

Downloads

0

Crossref

Received: 27 January 2026
Revised: 14 April 2026
Accepted: 30 April 2026
Published: 15 October 2026
© 2026 Editorial Board of Journal of Nanjing Medical University(Natural Sciences)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).